Nov 01, 2022 4:00pm EDT Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
Sep 26, 2022 7:00am EDT Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
Sep 09, 2022 8:00am EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress
Aug 23, 2022 5:00pm EDT Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26
Jul 05, 2022 6:00am EDT Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
Jun 23, 2022 4:00pm EDT Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
May 24, 2022 4:00pm EDT Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
May 11, 2022 9:00am EDT Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
